Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea

Current Medical Research and Opinion

Volumn 25, Issue 1, 2009, Pages 65-75

  Bergenstal, Richard ^a   Lewin, Andrew ^b   Bailey, Timothy ^c   Chang, Denise ^d   Gylvin, Titus ^d   Roberts, Victor ^e  

^a INTERNATIONAL DIABETES CENTER   (United States)

^b NATIONAL RESEARCH INSTITUTE   (United States)

^c AMCR Institute   (United States)

^d NOVO NORDISK INC   (United States)

^e Endocrine Clinical Research   (United States)

Author keywords

BIAsp 30; GLP 1; Incretin mimetic; Type 2 diabetes

Indexed keywords

BIPHASIC INSULIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; DRUG DERIVATIVE; INSULIN; INSULIN, ASP(B28)-; PEPTIDE; SULFONYLUREA DERIVATIVE; VENOM;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART PALPITATION; HUMAN; HUNGER; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; SELF MONITORING; SIDE EFFECT; SWEATING; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN; WEIGHT REDUCTION; BLOOD; MIDDLE AGED;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; SULFONYLUREA COMPOUNDS; VENOMS;

EID: 64249143715     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802597951     Document Type: Article

References (44)

1. Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104:787-794 (Pubitemid 29536364)
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986
3. Nathan DM, Cleary PA, Backlund JY , et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653 (Pubitemid 41817713)
4. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853 (Pubitemid 28416718)
5. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117
6. Wake N, Hisashige A, Katayama T, et al. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract 2000; 48:201-210 (Pubitemid 30232841)
7. Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(Suppl 2):B21-B29. UK Pros (Pubitemid 30185774)
8. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
9. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
10. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
11. Koro CM, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes. Diabetes Care 2004;27:17-20
12. Harris MI, Eastman RC, Cowie CC, et al. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999;22:403-408 (Pubitemid 29106894)
13. American Diabetes Association Position statement. Standards of Medical Care in Diabetes - 2008. Diabetes Care 2008;31 (Suppl 1):S12-54
14. Kvapil M, Mikolajczyk-Swtko A, Ostergaard A, et al. Biphasic insulin aspart 30 combined with metformin provides better glycemic control in poorly type 2 diabetic patients. Diabetes 2002;51(Suppl 2):Abstract 104
15. Kolterman OG, Buse JB, Finesman MS, et al. Synthetic exendin- 4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-3089 (Pubitemid 36877476)
16. Goke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exedin (9-39) amide an antagonist at the glucagon like peptide 1 (7-36) amide receptor of insulin-secreting beta cells. J Biol Chem 1993;268:19650-19655
17. American Diabetes Association. Position Statement. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2008;31:S55-60
18. World Medical Association. Declaration of Helsinki (2002) Ethical Principles for Medical Research Involving Human Subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Last amended with Note of Clarification on Paragraph 29 by the WMA General Assembly, Washington
19. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Good Clinical Practice. 01-May-1996
20. Nauck M, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50:259-267
21. Kendell DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-1091 (Pubitemid 40616617)
22. Raskin R, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes; a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-265 (Pubitemid 40170923)
23. Oyer DS, Shepherd MD, Coulter FC, et al. Efficacy and safety of dietary counseling coupled with initiation of biphasic insulin aspart 70/30 in type 2 diabetes patients - the INITIATE plus study. Diabetes 2007;56(Suppl 1):A552(2180-po)
24. Riddle MC, Rosenstock J, Gerich JE, et al. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy in type 2 diabetic patients. Diabetes Care 2003;26:3080-3086 (Pubitemid 37339502)
25. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice- or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006;8:58-66
26. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel treat-to-target trial comparing insulin Detemir with NPH insulin as add-on therapy to oral glucose lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care 2006;29:1269-1274 (Pubitemid 44125921)
27. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-451 (Pubitemid 43277866)
28. Kahn SE, Steven CB, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443 (Pubitemid 44903747)
29. Lund SS, Tarnow L, Pedersen OB, et al. REFORM Study: effect of BIAsp30 (NovoLog Mix 70/30) in combination with oral hypoglycaemic agents (OHA) on glycaemic control in non-obese patients with type 2 diabetes (T2DM). Diabetes 2005;54(Suppl 1):A126
30. 1c. IOEZ Study Group. Diabetes Care 2000;23:1236-1241
31. de Veciana M, Major CA, Morgan MA, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 1995;333:1237-1241
32. 1c. Diabetes Care 2003;26:881-885
33. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-265 (Pubitemid 40170923)
34. Goke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exedin (9-39) amide an antagonist at the glucagon like peptide 1 (7-36) amide receptor of insulin-secreting beta cells. J Biol Chem 1993;268:19650-19655
35. Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin. Invest 1998;101:515-520 (Pubitemid 28084232)
36. Byetta package insert. Amylin Pharmaceuticals, Inc., San Diego, CA; 2007 February
37. Vilsbøll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30:1608-1610 (Pubitemid 46871185)
38. Davis SN, Johns D, Maggs D, et al. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 2007;30:2767-2772 (Pubitemid 350083115)
39. Rosenstock J, Fonseca V. Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse. Diabetes Care 2007;30:2972-2973 (Pubitemid 350083155)
40. B O. Boehm, P. D. Home, C. Behrend, et al. Diabetic Med. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients Diabetic Med 2002;19:393-399
41. Davidson J, Christiansen JS, Brown P, et al. Biphasic insulin aspart has a lower risk of hypoglycemia than biphasic human insulin without compromising glycemic control: a metaanalysis of randomized controlled trials. Diabetes 2008;57 (Suppl. 1):A171
42. Drucker DJ, Buse JB, Taylor K, et al. for the DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2006;372: 1240-50. Published Online September 8, 2008. doi:10.1016/S0140-6736(08) 61206-4
43. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, doubleblind, randomized, controlled trial. Diabetes Care 2004; 27:1335-1342 (Pubitemid 38679980)
44. Nauck MA, Hompesch M, Filipczak R, et al. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycemic control and lowers body weight in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006;114:417-423 (Pubitemid 44620484)